This activity is provided by Integrity Continuing Education, Inc.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Until recently, the only treatment choices for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery, though endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery. To address this, novel biologics have been and continue to be evaluated for their impact on CRSwNP, giving clinicians treatment options beyond steroids and surgery for their patients with CRSwNP who are struggling to breathe freely. However, these new options necessitate education on clinical trial results for biologic therapy and on criteria for choosing between biologics and surgery, as well as patient education in regards to treatment with biologics. This program will increase understanding of new and emerging therapies, how they fit in with existing treatments, and best practices for the management of patients with CRSwNP.
Michael S. Blaiss, MD, FACAAI
Medical College of Georgia at Augusta University
This educational activity has been designed for allergists as well as nurse practitioners and physician assistants in allergy practice.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this Other activity (multichannel video and discussion) for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or email@example.com.
Michael S. Blaiss, MD, FACAAI
Consulting Fees: Amgen, AstraZeneca, GlaxoSmithKline, Merck, Regeneron, Sanofi
Speakers’ Bureaus: Regeneron, Sanofi
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
On the day of the program, you may access the event by going to the following link:
Livestream platform: https://integrityce.com/nasallive7
There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME Credit™. To do so, you must participate in the virtual livestream activity and complete the posttest and evaluation following the event. A statement of credit will be issued within four weeks of submission of a completed activity evaluation form.